Data Knights Acquisition (NASDAQ:DKDCA – Get Rating) and Charles River Laboratories International (NYSE:CRL – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Insider and Institutional Ownership
97.3% of Data Knights Acquisition shares are owned by institutional investors. Comparatively, 95.2% of Charles River Laboratories International shares are owned by institutional investors. 1.1% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Get
Data Knights Acquisition alerts:
Volatility and Risk
Data Knights Acquisition has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Data Knights Acquisition and Charles River Laboratories International, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Data Knights Acquisition | 0 | 0 | 0 | 0 | N/A |
| Charles River Laboratories International | 0 | 2 | 10 | 0 | 2.83 |
Charles River Laboratories International has a consensus target price of $314.33, suggesting a potential upside of 56.50%. Given Charles River Laboratories International's higher possible upside, analysts clearly believe Charles River Laboratories International is more favorable than Data Knights Acquisition.
Earnings and Valuation
This table compares Data Knights Acquisition and Charles River Laboratories International's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Data Knights Acquisition | N/A | N/A | $5.14 million | N/A | N/A |
| Charles River Laboratories International | $35.40 billion | 0.29 | $390.98 million | $8.62 | 23.30 |
Charles River Laboratories International has higher revenue and earnings than Data Knights Acquisition.
Profitability
This table compares Data Knights Acquisition and Charles River Laboratories International's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Data Knights Acquisition | N/A | N/A | N/A |
| Charles River Laboratories International | 12.02% | 21.51% | 7.68% |
Summary
Charles River Laboratories International beats Data Knights Acquisition on 9 of the 10 factors compared between the two stocks.
About Data Knights Acquisition
(Get Rating)
Data Knights Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. The company was incorporated in 2021 and is based in Chessington, the United Kingdom.
About Charles River Laboratories International
(Get Rating)
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Receive News & Ratings for Data Knights Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Data Knights Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
